OraSure Technologies (OSUR): Progress for Zika & Microbiome, Raising PT - Jefferies
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Jefferies analyst, Brandon Coulliard, reiterated his Buy rating on shares of OraSure Technologies (NASDAQ: OSUR) after two major positive pipeline developments add greater confidence in near term revenue forecasts & scope for upside to current consensus estimates including: 1) HHS/BARDA contract for rapid Zika test; and 2) third-party study data from Human Longevity (genomics industry KOL) endorsing OSUR's OMNIgene-GUT sample collection device as the de-facto gold-standard for all future microbiome studies.
Additional upcoming catalysts include: 1) Finalization of major HCV test supply contract (~$18M over ~1 yr period); 2) 510(k) submission & approval of rapid Ebola antigen test; 3) Launch of major new consumer genomics testing service (new DNAG customer); 4) possible M&A activities.
The price target increases to $10 from $8.
Shares of OraSure Technologies closed at $8.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asbury Automotive Group (ABG) PT Lowered to $55 at Jefferies
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- Graphic Packaging (GPK) PT, Estimates Trimmed at Jefferies Post Q3
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!